1. The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma
- Author
-
Chih-Ping Han, Wan-Ru Chao, Kuang-Leei Chang, and Ming-Yung Lee
- Subjects
0301 basic medicine ,endocrine system diseases ,Genes, BRCA2 ,Genes, BRCA1 ,Angiogenesis Inhibitors ,Carcinoma, Ovarian Epithelial ,medicine.disease_cause ,Kras mutation ,0302 clinical medicine ,Mucinous ovarian carcinoma ,Ovarian carcinoma ,Drug Discovery ,HER2 Amplification ,Neoplasm Metastasis ,skin and connective tissue diseases ,Letter to the Editor ,Early Detection of Cancer ,Ovarian Neoplasms ,Hybridization probe ,Her2 amplification ,Middle Aged ,Prognosis ,Adenocarcinoma, Mucinous ,030220 oncology & carcinogenesis ,Molecular Medicine ,Female ,KRAS ,Mucinous cystadenocarcinoma ,Hormone Replacement Therapy ,Antineoplastic Agents ,Poly(ADP-ribose) Polymerase Inhibitors ,Proto-Oncogene Proteins p21(ras) ,03 medical and health sciences ,Genetics ,medicine ,Humans ,Molecular Biology ,neoplasms ,Germ-Line Mutation ,business.industry ,medicine.disease ,digestive system diseases ,030104 developmental biology ,Mutation ,Cancer research ,Neoplasm Recurrence, Local ,Ovarian cancer ,business ,Forecasting - Abstract
Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. The disease typically presents in postmenopausal women, with a few months of abdominal pain and distension. Most women have advanced disease (International Federation of Gynecology and Obstetrics [FIGO] stage III), for which the standard of care remains surgery and platinum-based cytotoxic chemotherapy. Although this treatment can be curative for most patients with early stage disease, most women with advanced disease will develop many episodes of recurrent disease with progressively shorter disease-free intervals. These episodes culminate in chemoresistance and ultimately bowel obstruction, the most frequent cause of death. For women whose disease continues to respond to platinum-based drugs, the disease can often be controlled for 5 years or more. Targeted treatments such as antiangiogenic drugs or poly (ADP-ribose) polymerase inhibitors offer potential for improved survival. The efficacy of screening, designed to detect the disease at an earlier and curable stage remains unproven, with key results expected in 2015.
- Published
- 2016